AdvanCell Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 93

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $315M

  • Investors
  • 25

AdvanCell General Information

Description

Operator of radiopharmaceutical therapies intended to treat cancer using targeted alpha-emitting radionuclides. The company offers a proprietary lead-based radionuclide platform, integrated manufacturing, and clinical development capabilities, enabling healthcare providers to access targeted cancer therapies that improve treatment outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 245 Main Street
  • Cambridge
  • Boston, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 245 Main Street
  • Cambridge
  • Boston, MA 02142
  • United States

AdvanCell Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AdvanCell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series D) 15-Jul-2026 $315M Completed Clinical Trials - Phase 2
7. Grant 15-Apr-2025 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 24-Jun-2025 Completed Clinical Trials - Phase 2
5. Early Stage VC 27-Dec-2023 Completed Clinical Trials - Phase 2
4. Grant 27-Jun-2023 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 24-Aug-2022 Completed Clinical Trials - Phase 2
2. Grant 15-Dec-2021 $2.1M $1.65M Completed Startup
1. Early Stage VC (Series A) 18-Nov-2020 $1.65M $1.65M Completed Startup
To view AdvanCell’s complete valuation and funding history, request access »

AdvanCell Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
To view AdvanCell’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AdvanCell Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of radiopharmaceutical therapies intended to treat cancer using targeted alpha-emitting radionuclides. The comp
Drug Discovery
Boston, MA
93 As of 2026

Hamilton, Canada
 

Munich, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AdvanCell Competitors (7)

One of AdvanCell’s 7 competitors is Fusion Pharmaceuticals, a Formerly VC-backed company based in Hamilton, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fusion Pharmaceuticals Formerly VC-backed Hamilton, Canada
ITM Isotope Technologies Munich Private Equity-Backed Munich, Germany
RadioMedix Venture Capital-Backed Houston, TX
Artbio Venture Capital-Backed Cambridge, MA
RayzeBio Formerly VC-backed San Diego, CA
You’re viewing 5 of 7 competitors. Get the full list »

AdvanCell Patents

AdvanCell Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024903000-A0 Radioisotope generator Inactive 19-Sep-2024
WO-2026060494-A1 Radioisotope generator Pending 19-Sep-2024
WO-2026060494-A8 Radioisotope generator Pending 19-Sep-2024
AU-2023902414-A0 Dosage regimen comprising short-lived radioisotope Inactive 31-Jul-2023
US-20260284241-A1 Dosage regimen for short-lived radioisotope Pending 31-Jul-2023 A61K51/088
To view AdvanCell’s complete patent history, request access »

AdvanCell Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AdvanCell Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ally Bridge Group Growth/Expansion Minority
Alpha Wave Global Growth/Expansion Minority
Bain Capital PE/Buyout Minority
Eli Lilly and Company Foundation Limited Partner Minority
Eventide Asset Management Venture Capital Minority
You’re viewing 5 of 25 investors. Get the full list »

AdvanCell FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process